Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 747Carcinoma, Renal Cell 237Urinary Bladder Neoplasms 212Carcinoma, Transitional Cell 115Breast Neoplasms 100Kidney Neoplasms 97Neoplasms 91Carcinoma, Non-Small-Cell Lung 86Melanoma 82Ovarian Neoplasms 81Colorectal Neoplasms 76Neoplasm Metastasis 69Non-Muscle Invasive Bladder Neoplasms 58Lung Neoplasms 58Pancreatic Neoplasms 49Endometrial Neoplasms 46Sarcoma 43Stomach Neoplasms 42Uterine Cervical Neoplasms 41Carcinoma, Hepatocellular 36Adenocarcinoma 35Wilms Tumor 33Esophageal Neoplasms 33Triple Negative Breast Neoplasms 31Squamous Cell Carcinoma of Head and Neck 31Head and Neck Neoplasms 29Testicular Neoplasms 25Metastatic Castration-resistant Prostate Cancer 25Disease 24Colonic Neoplasms 24

Interventions

enzalutamide 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Hormone Sensitive Prostate Cancer × Genitourinary × 90 days × Clear all
NCT04076059 2026-04-17

China ARCHES

Astellas Pharma Inc

Phase 3 Active not recruiting
180 enrolled 24 charts
Genitourinary

Metastatic Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡